Table 1: Agents targeting AR in clinical development for CRPC.

Drug Mechanism of action Patient characteristics Phase of development Clinical trial registration number MDV-3100 AR antagonist Chemotherapy-treated Phase III NCT00974311 Chemotherapy-naïve Phase III NCT01212991 ARN-509 AR antagonist ND Phase I-II NCT01171898 AZD3514 AR antagonist ND Phase I-II NCT01162395 Abiraterone acetate CYP 17 inhibitor Chemotherapy-treated Phase III NCT00638690 Chemotherapy-naïve Phase III NCT00887198 Orteronel (TAK-700) CYP 17 inhibitor Chemotherapy-treated Phase III NCT01193257 VN/124-1 (TOK-001) AR downregulating agent, CYP 17 inhibitor, and AR antagonist ND Phase I-II NCT00959959

ND: not defined.